HCC Monitor
September 2016
Volume: 2
Issue: 3
June 2016
Volume: 2
Issue: 3
April 2016
Volume: 2
Issue: 1
October 2015
Volume: 1
Issue: 3
July 2015
Volume: 1
Issue: 2
April 2015
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Type C Meeting Supports Phase 3 Design for DLL3-Targeted ADC in ES-SCLC
2
FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
3
Zanidatamab/Chemo Achieves OS Benefit in HER2+ Gastroesopheageal Cancer
4
FDA Approval Sought for Selinexor Plus Ruxolitinib in Myelofibrosis
5